Analysis shows that vidaza prolongs survival in patients with higher-risk myelodysplastic syndromes

December 10, 2008

Crosswicks, NJ - (December 10, 2008) - The Myelodysplastic Syndromes (MDS) Foundation announced today that a subanalysis of the AZA-001 phase III international clinical trial shows that treatment with VIDAZA (azacitidine) can extend overall survival and reduce the risk of death in elderly higher-risk MDS patients.

Dr. John F. Seymour of the Peter MacCallum Cancer Institute in Victoria, Australia presented the analysis at the 50th Annual Meeting of the American Society of Hematology in San Francisco. The results showed that 55 percent of patients in the trial had significantly higher overall survival rates at two years when treated with VIDAZA, as compared to patients treated with conventional care regimens (CCR).

"Dr. Seymour's analysis shows the major recent clinical advancements in treatments for elderly, higher-risk MDS patient," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation. "We are hopeful about the potential of new therapies, like VIDAZA, which are helping MDS patients to live longer and with a better quality of life."

The analysis presented by Dr. Seymour is a follow-up to results from the AZA-001 trial, presented at the American Society of Clinical Oncology meeting in June, which showed that VIDAZA significantly extends overall survival for patients with MDS compared to conventional care regimens. Patients who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
-end-
About MDS

MDS is a cancer in which the bone marrow fails to make enough functioning blood cells, either red blood cells, white blood cells or platelets. It is not known exactly how many people have MDS, however, about 20,000 to 25,000 new cases are diagnosed annually in the U.S. In addition, roughly 30 percent of patients diagnosed with MDS will progress to acute myeloid leukemia (AML).

About the MDS Foundation

The Myelodysplastic Syndromes Foundation, Inc. is a multi-disciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases. For further information, please visit http://www.mds-foundation.org.

MDS Foundation

Related Myelodysplastic Syndromes Articles from Brightsurf:

Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following a
A research group led by Assistant Professor Takaaki Konuma in the Department of Hematology/Oncology, the Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT Hospital) has demonstrated a graft-versus-tumor (GVT) effect of a previously unknown/novel allogeneic hematopoietic cell transplantation in MDS patients.

RTL1 gene a likely culprit behind temple and Kagami-Ogata syndromes
Researchers from Tokyo Medical and Dental University (TMDU) have found that Rtl1, which is a mouse ortholog of the human RTL1 gene, appears to be the major gene responsible for muscle and placental defects in models of Temple and Kagami-Ogata syndromes, which are serious genetic conditions.

Identified gene mutations impact on the severity of a type of hematologic cancer
Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene's copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population.

Identified the genetic landscape of myelodysplastic/myeloproliferative neoplasms
Researchers from the MDS Group of the Josep Carreras Leukaemia Research Institute and the Munich Leukemia Laboratory map the mutations that can ease and accelerate the diagnosis of Myelodysplastic/Myeloproliferative Neoplasms rare malignancies.

Merits of revascularisation and medical treatment for chronic coronary syndromes
There are two treatment goals for patients with chronic coronary syndromes: reducing the risk of hard outcomes (i.e., death, myocardial infarction) and improving health outcomes (i.e. angina symptoms, quality of life).

New treatment target verification for myelodysplastic syndrome
A Japanese research group analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered be a tumor suppressor.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

A new facial analysis method detects genetic syndromes with high precision and specificity
Developed by Araceli Morales, Gemma Piella and Federico Sukno, members of the Department of Information and Communication Technologies, together with researchers from the University of Washington, which they present in a feature in the advanced online edition of Lecture Notes in Computer Science of Oct.

Published a clinical guide for the genomic diagnosis of Myelodysplastic Syndromes and Chronic Myelomonocytic leukaemia
A collective work between researchers from 8 research centres and hospitals in Spain, coordinated by Francesc Solé of the Josep Carreras Leukaemia Research Institute (IJC), and Esperanza Such, of the University and Polytechnic Hospital de la Fe describes the recommendations of use of the Next Generation genome Sequencing (NGS) in the diagnosis of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Pollution and noise reduction advised in ESC guidelines on chronic coronary syndromes
The detrimental impact of pollution and noise on patients with chronic coronary syndromes is highlighted for the first time in European Society of Cardiology (ESC) Guidelines published online today in European Heart Journal, and on the ESC website.

Read More: Myelodysplastic Syndromes News and Myelodysplastic Syndromes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.